Please assess the completion status of the following clinical trial:

Trial Title: Feasibility Study of Post-hospitalization Interventions to Improve Physical Function in Older Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE1
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Admitted to the University of Texas Medical Branch (UTMB) ACE unit with an admitting diagnosis of congestive heart failure, respiratory infection, kidney/urinary tract infection, or metabolic disorder; or other condition that will allow a subject to participate in the study after patient review~* Aged 65 years or older~* Self-reported ability (with or without the aid of an assistive device) to walk across a small room two weeks prior to hospitalization~* Lives within 30 miles of UTMB~* Can stand without assistance at the time of pretesting~* Presents no medical contraindication to wearing a loose fitting velcro strap for the accelerometer on one ankle~* Score ≥26 on the 30-item Mini Mental State Examination or alert and oriented X3 by physician on H\&P~* Is discharged to home at ACE unit discharge.~Exclusion Criteria:~* Nursing home resident or hospice patient~* Uncontrolled blood pressure (systolic \>150, or diastolic \> 100)~* History of stroke with motor disability~* Glomerular filtration rate (GFR) \<30 mL/min/1.73m2 or evidence of kidney disease or failure~* Liver disease ( aspartate aminotransferase (AST) /Alanine transaminase (ALT) 2 times above the normal limit, hyperbilirubinemia)~* Recent (within 3 months) treatment with anabolic steroids~* Any other condition or event considered exclusionary by the PI and faculty physician~* Planned or elective hospitalization within 30 days of discharge~Additional Exclusion Criteria for Subjects Randomized to the Testosterone Group~* Breast or prostate cancer~* Palpable prostate nodule or induration or prostate specific antigen (PSA) ≥ 4 ng/ml~* PSA ≥ 3 ng/ml in men at high risk of prostate cancer, such as African Americans or men with first-degree relatives with prostate cancer~* Hematocrit ≥ 50%~* Decompensated heart failure as determined by a physician

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo Supplement (Type: PLACEBO_COMPARATOR): Daily placebo supplement for 30 days after discharge.
- Nutritional Supplement (Type: EXPERIMENTAL): Daily nutritional supplement for 30 days after discharge.
- In-home exercise + placebo (Type: EXPERIMENTAL): in-home exercise 3 times a week and daily placebo supplement for 30 days after discharge.
- In-home exercise + nutrition (Type: EXPERIMENTAL): in-home exercise 3 times a week and daily nutritional supplement for 30 days after discharge.
- Testosterone (Type: EXPERIMENTAL): Single testosterone injection within 24 hours of hospital discharge.

Based on this trial design, predict the completion outcome and termination type (if applicable).